Table 1. Baseline characteristics and outcomes by low-density lipoprotein cholesterol response to statin therapy.
| Total n (%) 1029 (100) | Suboptimal statin responders n (%) 573 (55.6) | Optimal statin responders n (%) 456 (44.3) | p-value | ||
|---|---|---|---|---|---|
| Age (median, IQR, mg/dL) | 53/61/69 | 53/61/69 | 53/61/69 | 0.684 | |
| Gender (Female, n (%)) | 221 (21.5) | 121 (21.1) | 100 (21.9) | 0.761 | |
| Hypertension, n (%) | 655 (63.7) | 379 (66.1) | 276 (60.5) | 0.068 | |
| Prior myocardial infarction, n (%) | 56 (5.4) | 46 (8) | 10 (2.2) | <0.001 | |
| Prior coronary revascularization, n (%) | 103 (10) | 81 (14.1) | 22 (4.8) | <0.001 | |
| Diabetes mellitus, n (%) | 311 (30.2) | 180 (31.4) | 131 (28.7) | 0.374 | |
| Smoking, n (%) | 727 (70.7) | 415 (72.4) | 312 (68.4) | 0.169 | |
| Baseline LDL-C (median, IQR, mg/dL) | 111/133/159 | 103/124/150 | 120/145/171 | <0.001 | |
| Baseline HDL-C (median, IQR, mg/dL) | 34/40/46 | 33/38/45 | 36/41/47 | <0.001 | |
| Baseline triglyceride (median, IQR, mg/dL) | 72/112/176 | 74/115/179 | 71/109/171 | 0.290 | |
| Baseline total cholesterol (median, IQR, mg/dL) | 169/198/227 | 162/189/218 | 178/208/241 | <0.001 | |
| hs-CRP (median, IQR, mg/dL) | 3/3.4/6.1 | 3/3.7/6.7 | 3/3/5.7 | 0.003 | |
| Admission glucose (median, IQR, mg/dL) | 154.6±86 | 102/125/169 | 102/125/172 | 0.821 | |
| On-treatment LDL-C (median, IQR, mg/dL) | 70/88/112 | 84/106/130 | 63/72/85 | <0.001 | |
| Follow-up times (median, IQR, months) | 31/48/64 | 31/48/65 | 30/45/64 | 0.105 | |
| Statin therapy, n | Atorvastatin 40 mg | 562 | 301 | 220 | >0.05 |
| Atorvastatin 80 mg | 458 | 268 | 231 | ||
| Rosuvastatin 20 mg | 5 | 2 | 3 | ||
| Rosuvastatin 40 mg | 4 | 2 | 2 | ||
| MACE, n (%) | 339 (32.9) | 299 (52.2) | 40 (8.8) | <0.001 | |
| Cardiovascular death, n (%) | 35 (3.4) | 29 (5.1) | 6 (1.3) | 0.001 | |
| Reinfarction, n (%) | 89 (8.6) | 85 (14.8) | 4 (0.9) | <0.001 | |
| Recurrent myocardial infarction n (%) | 260 (25.3) | 235 (41) | 25 (5.5) | <0.001 | |
| Target vessel revascularization, n (%) | 321 (31.2) | 283 (49.4) | 38 (8.3) | <0.001 | |
Data were shown as mean±standard deviation and n (%).
IQR: interquartile range; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; MACE: major adverse cardiovascular events.
Bold values indicate statistical significance at the p<0.05 level.